Amgen’s Phase III data supports FDA label expansion of Repatha

Amgen's Repatha (evolocumab) has demonstrated long-term efficacy in reducing major adverse cardiovascular events (MACE) in high-risk patients without prior heart attack or stroke, as evidenced by its VESALIUS-CV Phase III trial data. This positive outcome validates the drug's recently widened FDA label, significantly expanding its addressable market and projecting peak sales of $3.87 billion in 2029. However, Repatha faces increasing competition, notably from Novartis' Leqvio, which is forecast to reach $3.98 billion by 2031, and its patent expiry in 2030 is expected to lead to a subsequent decline in sales.

Analysis

Amgen's (AMGN) Repatha has received a significant boost from the successful Phase III VESALIUS-CV trial, which met both primary endpoints for reducing major adverse cardiovascular events (MACE) in high-risk patients without a prior history of heart attack or stroke. This result validates a recent label expansion, potentially opening the drug to an addressable market of tens of millions more patients and supporting GlobalData's peak sales forecast of $3.87 billion in 2029. However, this positive medium-term outlook is tempered by two significant long-term headwinds. First, Repatha's patent is set to expire in 2030, creating an opening for biosimilars and leading to a projected sales decline to $3.32 billion by 2031. Second, competition is intensifying, most notably from Novartis's (NVS) Leqvio, which is forecast to achieve sales of $3.98 billion by 2031, surpassing Repatha. While Amgen has successfully defended its position against Regeneron (REGN) and Sanofi's (SNY) Praluent, the rise of Leqvio and other pipeline assets from competitors like AstraZeneca and NewAmsterdam Pharma signals a highly competitive dyslipidemia market, which is expected to reach $15.53 billion by 2032.

Key Decisions for Investors

• While the positive trial data de-risks Repatha's revenue stream until its 2030 patent cliff, investors should monitor the full data presentation on November 8th for specifics on the magnitude of clinical benefit, which will be critical for driving adoption.
• The primary long-term risk to Amgen's franchise is competitive pressure, specifically from Novartis's Leqvio, which is projected to overtake Repatha in sales by 2031; therefore, tracking Leqvio's market penetration and sales growth is essential for gauging the erosion of Repatha's market share post-2029.
• Given the defined patent expiry in 2030, focus should be placed on Amgen's strategy to mitigate the upcoming revenue loss, including pipeline developments in its cardiovascular portfolio or other therapeutic areas.